RT Journal
A1 Anker SD, von Haehling S
T1 VItamin d therapy and cardiac function in chronic kidney disease—reply
JF JAMA
JO JAMA
YR 2012
FD June 6
VO 307
IS 21
SP 2253
OP 2253
DO 10.1001/jama.2012.4178
UL http://dx.doi.org/10.1001/jama.2012.4178
AB 
In Reply: We agree with Dr Slatopolsky that many aspects merit attention in the discussion of paricalcitol. We also agree that paricalcitol is effective and even faster than 1,25-hydroxyvitamin D3 in the suppression of elevated levels of parathyroid hormone.1 This is also the case in patients with significantly elevated levels of phosphorus, a subgroup of patients usually deemed resistant to 1,25-hydroxyvitamin D3.2 However, in the space of an editorial, we were not able to provide a complete overview of paricalcitol and therefore primarily focused on summarizing the evidence in the field of CKD and left ventricular hypertrophy, which was the area of concern for the PRIMO trial. No beneficial effects of paricalcitol have yet been demonstrated in this regard.